Brokerages Set Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Price Target at $246.06

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have been assigned an average rating of “Moderate Buy” from the nineteen ratings firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and sixteen have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $246.0588.

A number of equities analysts have issued reports on the company. Royal Bank Of Canada upped their target price on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Wells Fargo & Company upped their target price on Jazz Pharmaceuticals from $250.00 to $265.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Truist Financial set a $256.00 target price on Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, June 9th. Weiss Ratings lowered Jazz Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday. Finally, Bank of America upped their target price on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $226.88 on Friday. The business’s 50 day moving average is $219.28 and its two-hundred day moving average is $189.60. Jazz Pharmaceuticals has a 52-week low of $105.00 and a 52-week high of $243.32. The firm has a market cap of $14.25 billion, a price-to-earnings ratio of -11,338.33, a PEG ratio of 0.20 and a beta of 0.32. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The company had revenue of $1.07 billion for the quarter. Analysts forecast that Jazz Pharmaceuticals will post 22.09 EPS for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 1,200 shares of the business’s stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total value of $278,196.00. Following the completion of the sale, the executive vice president directly owned 51,549 shares in the company, valued at approximately $11,950,604.67. The trade was a 2.27% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Heather Ann Mcsharry sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $241.00, for a total value of $482,000.00. Following the completion of the sale, the director owned 18,449 shares of the company’s stock, valued at $4,446,209. This trade represents a 9.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 11,941 shares of company stock valued at $2,565,339 over the last 90 days. Insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently made changes to their positions in JAZZ. Royal Bank of Canada increased its holdings in shares of Jazz Pharmaceuticals by 96.5% in the 1st quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock valued at $8,394,000 after acquiring an additional 33,210 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Jazz Pharmaceuticals by 147.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock valued at $43,652,000 after acquiring an additional 209,667 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Jazz Pharmaceuticals by 4.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock valued at $24,479,000 after acquiring an additional 7,954 shares during the last quarter. Focus Partners Wealth increased its holdings in shares of Jazz Pharmaceuticals by 3.4% in the 1st quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock valued at $574,000 after acquiring an additional 154 shares during the last quarter. Finally, Geneos Wealth Management Inc. increased its holdings in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 137 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.